Akari Therapeutics, Plc Securities Litigation

If you purchased a significant amount of shares of Akari Therapeutics Plc (NASDAQ: AKTX), you have certain options. Investors should register for updates.

 

Lawsuit Overview

Defendant:Akari Therapeutics Plc
Date Filed:May 12th, 2017
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:April 24th, 2017
Class End Date:May 30th, 2017
Settlement Website: http://www.strategicclaims.net/akari-therapeutics-plc-securities-litigation/
Settlement Deadline:October 15th, 2018

According to the law firm press release, the complaint filed in this class action lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company\'s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company\'s CEO, and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; (2) that the Company lacked adequate checks and protections to prevent such behavior; and (3) that, as a result of the foregoing, Defendants\' statements about Akari\'s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Akari Therapeutics Plc

 
First Identified Complaint

Derek Da Ponte, et al. v. Akari Therapeutics, Plc, et al.

Date Filed:May 12th, 2017
Class Period Start:March 30th, 2017
Class Period End:May 11th, 2017
First Identified Complaint Filings
#Document TitleFiling Date